Clinical trial of rosuvastatin calcium tablets in the treatment of patients with primary hypercholesterolemia
10.13699/j.cnki.1001-6821.2017.15.009
- VernacularTitle:瑞舒伐他汀钙片治疗原发性高胆固醇血症的临床研究
- Author:
Yu-Feng QU
1
;
Gui-Zhi ZONG
Author Information
1. 北京京煤集团总医院 内分泌科
- Keywords:
primary hypercholesterolemia;
atorvastatin calcium tablet;
rosuvastatin calcium tablet;
hypersensitive C-reactive protein;
soluble vascular cell adhesion molecule 1
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(15):1412-1414
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy of rosuvastatin calcium tablets in the treatment of patients with primary hypercholesterolemia and its effects on the serum high sensitivity reactive protein (hs-CRP) and soluble vascular cell adhesion factor-1 (sVCAM-1).Methods Eighty-six patients with primary hypercholesterolemia were divided into treatment group and control group,43 cases in each group.Control group was treated with atorvastatin calcium tablets 10 mg · d-1,orally.Treatment group was treated with rosuvastatin calcium tablets 10 mg · d-1,orally.All patients were treated for 8 weeks.The clinical efficacy,blood lipids and levels of serum hs-CRP,sVCAM-1 were compared between two groups.Results After treatment,the total effective rates in treatment group and control group were 95.35％ (41/43 cases),79.07％ (34/43 cases),with significant difference (P ＜ 0.05).The total cholesterol (TC),triglyceride (TG) and low-density lipoprotein (LDL-C) in treatment group were (4.38±0.89),(1.54 ±0.79),(2.23 ± 0.82) mmol · L-1,had significant difference with those in control group,which were (4.79 ± 0.87),(1.90 ± 0.83),(2.61 ± 0.89) mmol· L-1(P ＜ 0.05).The levels of hs-CRP in treatment group and control group were (4.83 ± 1.13),(5.12 ± 1.78) mg · L-1 The levels of sVCAM-1 in treatment group and control group were (0.37 ± 0.15),(0.39 ±0.13) mg· L-1,with significant difference (P＜0.05).The adverse drug reactions in two groups were constipation,abdominal pain,nausea.The incidence of adverse drug reactions in treatment group and control group were 11.63％ (5/43 cases),13.95％ (6/43 cases),without significant difference (P ＞0.05).Conclusion Rosuvastatin calcium tablet has good clinical efficacy in the treatment of primary hypercholes-terolemia,with high safety.
